BIOMEDICAL ENGINEERING
focusing much of its efforts on providing such evidence as well as working with its partners on the science of scaling through working with local partners such as the CLAHRC (Centre for Leadership and Applied Health Research) and understanding the recent outputs of the Kings Fund and Health Foundation report.
There are several major opportunities where system-wide innovation could contribute to keep people well, reduce pressure on health and care providers, support economic growth, and improve health outcomes for citizens and patients. The first opportunity is to recognise that the future of healthcare and medicine will be driven by: l Exciting advances in basic research, particularly in genomics, digital technologies
l The development of health data analytics, using integrated big data sets
l The use of citizen-level health pathways, to evaluate treatments and care pathways.
The second opportunity is to develop new approaches to working with industry: l Employing streamlined and accelerated decision-making structures to aid industry in navigating disjointed systems
l Developing new business models to enable us to tackle the perverse incentives in existing health and care funding which inhibit investment
l Develop funding models which incentivise providers to invest in innovation.
Perhaps the biggest change that could be made is to stop silo budgeting between different parts of the health and social care system, and to also prevent in-year or short term budgeting based decisions. Health Innovation Manchester will enhance Greater Manchester’s position, showcasing our city-region’s capabilities by aligning local, regional and national initiatives and strategies. Our strategic priorities align with and support not only the Greater Manchester-wide Digital Strategy but also the national Accelerated Access Review and the Life Sciences Industrial Strategy, highlighting Greater Manchester as an exemplar site.
Thriving innovation
A combination of knowledge, research, investment and facilities means that the region is a hotspot for healthcare innovation; universities, hospitals, science park and numerous successful tech start-ups. In fact, Greater Manchester is fast emerging as a global hub for the life sciences sector, healthcare innovation and clinical research. The number of bioscience companies operating in the region has grown by 86% over the past 10 years, representing a combined GVA (Gross Value Added) of £4 bn. Fuelled partly by its impressive collection of large, research-intensive universities, the region offers one of the largest clusters of NHS organisations and patient recruitment programmes for clinical research in the UK.
JUNE 2018
3 8
Fragmented and slow decision making
Structures which do not assist collaboration and coordination
Lengthy and uncertain routes to adoption
Excellent initiatives in one locality are not shared across the system
It is also home to some 13,000 health and life sciences graduates and over 157,000 health and social care workers.
These strengths are made effective through extensive collaboration and cooperation across sectors, companies and organisations. This is actively facilitated by local government and dedicated organisations such as: TRUSTECH, Health Innovation Manchester (as part of the National Academic Health Science Network), Corridor Manchester, Manchester Science Partnerships, the Manchester Growth Company and the Northern Health Science Alliance.
TRUSTECH operates within this system, working closely with all, with HInM continuing to bridge the gap between NHS providers and commissioners, and the commercial, academic and international healthcare sectors. It was one of the first NHS innovation hubs formed by the Department of Health in 2001 and aims to improve healthcare in the UK – and globally – through the development of innovative products and services. How? By incubating and nurturing innovative ideas, and offering services around this such as help with intellectual property, product development, trials and research. Certainly, there is more the NHS could be doing in terms of recognising the revenue that could be generated by innovation, which is an area that TRUSTECH has a focus on. There is a vast amount of valuable expertise, knowledge, and ideas to extract from the NHS. Some of the innovations we have worked with have originated from clinicians and healthcare workers and clinical entrepreneurs whose success should be celebrated. However, something that TRUSTECH and HInM hold in high regard is the need for healthcare providers to collaborate with other businesses. One of the challenges that the NHS faces is the view that all the answers lie within our own hands. Healthcare professionals are the source of many incredible ideas, that is true, and we often assist NHS staff push their innovations
Industry find multiplicity of organisations/initiatives confusing and add to risk
The obstacles preventing rapid implementation of innovations nationwide.
to the forefront, yet many great ideas also come from outside. Products and services used in other industries for instance can provide benefits to healthcare. Part of this includes not only capturing and scaling the innovative excellence within the local system but also those that have been shown to be effective in other regions. A more innovative NHS supports the UK’s aim to be a global hub for life sciences, and stronger economic growth; patients benefit from quicker access to innovative, cost- effective drugs, devices and diagnostics. Greater Manchester has recently signed an MOU with the Association of British Pharmaceutical Industries (ABPI) and is working closely with The Association of British Healthcare Industries (ABHI) to do the same, to bring forward a pipeline of innovations for rapid adoption.
Clinical research excellence
Our ambition is for Greater Manchester, one of the UK’s three biomedical clusters, to become a world-leading location for clinical research. The region’s single health and social care system is now providing greater impetus to deliver clinical research at pace and scale, where every patient is provided with the opportunity to be involved in research because it is at the heart of our innovative clinical practice. This will deliver both better health outcomes and economic growth. In taking our research ambitions forward, we are supported by first-rate people, services and infrastructure. This ranges from an internationally recognised NIHR biomedical research centre and clinical research facility, through to bespoke services, designed to support and facilitate the research process. Manchester is in the enviable position of global hotspot for innovation in healthcare; a combination of academia, research, skilled workforce, Europe’s biggest hospital site, alongside decisions being made locally as a result of devolution. Our thriving healthcare industry is uniquely placed to lead the way.
WWW.CLINICALSERVICESJOURNAL.COM I 73
CSJ
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80
